Panel-reactive antibodies are widely regarded as an important immunological risk factor for rejection and graft loss. The broadness of sensitization against HLA is most appropriately measured by the "calculated population-reactive antibodies" (cPRA) value. In this study, we investigated whether cPRA represent an immunological risk in times of sensitive and accurate determination of pretransplantation donor-specific HLA antibodies (DSA). Five hundred twenty-seven consecutive transplantations were divided into four groups: cPRA 0% (n = 250), cPRA 1-50% (n = 129), cPRA 51-100% (n = 43), and DSA (n = 105). Patients without DSA were considered as normal risk and received standard immunosuppression without T celldepleting induction. Patients with DSA received an enhanced induction therapy and maintenance immunosuppression. Surveillance biopsies were performed at 3 and 6 months. Median follow-up was 5.7 years. Among the three cPRA groups, there were no differences regarding the 1-year incidence of ABMR (p = 0.16) and TCMR (p = 0.75). The 5-year allograft survival rates were similar and around 87% (p = 0.28). The estimated glomerular filtration rate at last follow-up was 50-53 mL/min (p = 0.45). On multivariable Cox proportional hazard analysis, the strongest independent predictor for ABMR and (deathcensored) graft survival was pretransplantation DSA. cPRA were not predictive for ABMR, TCMR, or (deathcensored) graft survival. We conclude that with current DSA assignment, the broadness of sensitization measured by cPRA does not imply an immunological risk.
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Introduction
The broadness of sensitization is widely used as an immunological parameter for pretransplantation risk stratification in renal allograft recipients (1) (2) (3) (4) (5) . Traditionally, panels of T cells with or without B cells from 10-60 individuals were compiled and incubated with the sera of allograft recipients (6) . The binding of the recipient's HLA antibodies to the cells in the panel was detected with use of a complement-dependent cytotoxicity assay, and the broadness of sensitization was calculated as the proportion of positive reactions in the cell panel (panel reactive antibodies [PRA] ). Since the introduction of single HLA-antigen flow beads (SAB), the HLA antibody specificities of an allograft recipient can be precisely defined (7) . This information can be used to calculate against which proportion in a population the allograft recipient has reactive HLA antibodies (calculated population reactive antibodies [cPRA]) (8) . cPRA reflect the broadness of sensitization more accurately and has a lower center-tocenter variability compared with PRA (8) . For these reasons, cPRA have been adopted in many renal allograft allocation systems as a measure for the broadness of sensitization and to enhance access of sensitized patients to suitable organs (9, 10) .
SAB technology has also revolutionized preransplantation risk assessment, because the presence or absence of donor-specific HLA antibodies (DSA) can be determined precisely (11, 12) . This raises the question of whether the broadness of sensitization (i.e. cPRA) is still useful to predict the occurrence of rejection and allograft loss in times of modern DSA assignment. Dunn et al were the first to challenge the value of PRA for the prediction of pertinent outcomes posttransplantation (13) . They found that DSA were strongly associated with the occurrence of antibody-mediated rejection (ABMR), T cell-mediated rejection (TCMR), and death-censored allograft loss, while PRA were not, or to a much lesser extent. However, this study had some limitations such as universal use of T cell-depleting induction therapy in all patients, lack of surveillance biopsies, and PRA estimation by Luminex LabScreen PRA assay instead of cPRA, which in summary might limit broad applicability of their reported results (13) .
Therefore, the aim of this study was to investigate whether the broadness of sensitization by means of cPRA represents an immunological risk when modern DSA assignment is used. We took advantage of a cohort in which presence or absence of DSA was used for risk stratification and application of a T cell-depleting induction therapy, in which surveillance biopsies were performed at 3 and 6 months posttransplantation and which had a median follow-up of 5.7 years.
Materials and Methods

Patient population and risk stratification
This retrospective single-center study was approved by the Ethics Committee of Northwestern and Central Switzerland (www.eknz.ch). From 2005 to 2014, 618 renal transplantations were performed at the University Hospital Basel. For this study, we excluded 91 transplantations for the following reasons: (1) ABO-incompatible transplantations (n = 58), (2) transplantation from an HLA-identical sibling (n = 17), and (3) assumed high immunological risk in the absence of circulating DSA such as transplantations from husband to wife with shared children or transplantations from child to mother (n = 16). Thus, the final population consisted of 527 consecutive transplantations, in which a uniform immunological risk stratification based on the presence (n = 105) or absence (n = 422) of pretransplantation DSA was used. Pretransplantation DSA assignment was performed by virtual crossmatching and included current and remote HLA antibodies with a mean fluorescence intensity (MFI) > 500 (14, 15) . Both current and remote DSA were regarded as a risk for transplantation but not as a contraindication (14) (15) (16) . To proceed to transplantation, patients with pretransplantation DSA were required to have negative current T and B cell complement-dependent cytotoxicity (CDC) crossmatches; no MFI thresholds of DSA were used.
Immunosuppression
Patients with pretransplantation DSA received an induction therapy with a polyclonal T cell-depleting agent (Thymoglobulin total dose 6 mg/kg body weight or ATG-Fresenius total dose 21 mg/kg body weight) plus intravenous immunoglobulins (total dose 2 g/kg body weight). None of these patients received rituximab or bortezomib. Patients without pretransplantation DSA received induction therapy consisting of 20 mg basiliximab on days 0 and 4. The maintenance immunosuppression regimens were based on tacrolimus (Tac; Prograf, Astella, Wallisellen, Switzerland), mycophenolic acid (MPA: CellCept, Roche, Basel, Switzerland, or Myfortic, Novartis, Basel, Switzerland), and steroids. While steroids were continued indefinitely in patients with pretransplantation DSA, we aimed to achieve a steroid-free dual immunosuppression in all other patients beyond the first 3 months posttransplantation (14, 15, 17) .
Allograft biopsies and histopathology
Indication biopsies were performed at any time in case of inadequate graft function, serum creatinine increase >20% from baseline, or new onset of significant proteinuria. In addition, surveillance biopsies were scheduled for all patients at 3 and 6 months posttransplantation. Overall, 1335 biopsies were performed among the 527 transplant recipients during the first year posttransplantation. Only 35 (7%) of 527 patients did not have a biopsy performed within the first year posttransplantation. For specimen sampling, we used 16-gauge needles and routinely obtained two cores to minimize sampling error. Histological workup followed standard procedures and included light microscopy and immunofluorescence. Electron microscopy examination was performed if necessary for diagnosis on an individual basis. C4d staining was performed with immunofluorescence on frozen sections. All indication and surveillance biopsies were scored according to the Banff classification, which was valid for the corresponding time frame (18) (19) (20) (21) (22) . Mixed rejection episodes were allocated to the ABMR group.
Calculated population-reactive antibodies
All patients were screened for the presence of pretransplantation HLA antibodies by SAB technology (FlowPRA SA until December 2006, Luminex SA since December 2006; OneLambda) (14) . Therefore, we had a detailed assessment of HLA antibody specificities for each patient in the study. We retrospectively determined peak and last cPRA values based on all available SAB data. All specificities in the A/B/DRB1-5/DQB1 loci with MFI > 500 were included for cPRA calculation. Allele-specific HLA antibodies were included if the frequency of the targeted allele was >50% for the corresponding antigen. We used our own cPRA calculation tool based on 1584 persons typed for A/B/DRB1-5/DQB1 loci in our HLA laboratory. The obtained cPRA values are in very good agreement with cPRA values calculated by using the EuroTransplant vPRA tool (https:// www.etrl.org/Virtual%20PRA/Default.aspx). cPRA calculation was performed by a person who was blinded regarding the DSA status and clinical outcomes of the patients (H.C.).
Grouping according to pretransplantation DSA and last cPRA values
Based on the presence or absence of pretransplantation DSA and the last cPRA value, the 527 transplants were divided into four groups: (1) DSA (n = 105), (2) cPRA 0% (n = 250), (3) cPRA 1-50% (n = 129), and (4) cPRA 51-100% (n = 43). We decided to use the last cPRA value for grouping, because it is consistently available for all patients, whereas peak cPRA value is much more subject to serum availability at the supposed peak time points.
Data collection and statistical analysis
All relevant baseline and outcome data were extracted retrospectively from patient charts, histology reports, as well as the laboratory information system, and stored in a dedicated database. Data were then analyzed by using JMP Version 12 software (SAS Institute Inc., Cary, NC). Categorical data are presented as counts and/or percentages and were analyzed by using Pearson's v 2 test or Fisher's exact test as appropriate. Continuous data are shown as median and interquartile ranges (IQRs) and compared by the us of Wilcoxon rank sum tests. For all tests, a (two-tailed) p-value <0.05 was considered to indicate statistical significance. Time-to-event analyses were performed by using the Kaplan-Meier method and compared by using the log-rank test. Multivariable analysis to assess independent predictors for allograft rejection and allograft loss was performed by using the Cox proportional hazard method. ROC statistics were used to describe the relationship of the strength of pretransplantation DSA and the occurrence of rejection and death-censored graft loss.
Results
Baseline characteristics of recipients and donors
The baseline characteristics are summarized in Table 1 .
As expected, there were significant differences regarding the rate of female participants and sensitizing events among the four groups. By contrast, recipient and donor ages, as well as HLA mismatches, were similar. Due to the used risk stratification and selection of immunosuppression as detailed in the Method section, both maintenance and induction therapies were different. Six of 105 patients with DSA (6%) did not receive ATG induction as intended by the protocol. This was related to retrospective correction of DSA assignments. Eleven of 172 patients in the cPRA 1-50% and cPRA 50-100% groups (6%) did receive ATG induction instead of basiliximab. The main causes for this protocol violation were retrospective correction of DSA assignment and the use of ATG as a calcineurin inhibitor-sparing regimen in deceased donor transplants with a presumed intense ischemic injury. Retrospective corrections of DSA assignments were necessary when the deceased donor HLA typing-and thus the risk stratification by virtual crossmatching-was incomplete at the time of transplantation. The complementary HLA typing was performed within 2 days and the risk assignment adapted.
cPRA distribution and the impact of sensitizing events The distribution of peak and last cPRA values is shown in Figure 1 . The peak cPRA value was, by definition, higher than the last cPRA value, but the difference was rather small. The proportion of patients with 0% peak and last cPRA was 43% and 48%, respectively. All sensitizing events (i.e. blood transfusion, pregnancy, prior transplantation) significantly increased the rate and broadness of sensitization by means of cPRA. Interestingly, we observed a clear hierarchy of sensitizing events regarding their potential to induce an HLA antibody response ( Figure 2 ). Prior transplantations had the strongest impact, followed by pregnancies and blood transfusions.
Allograft rejection and loss
All patients had a minimal follow-up of 1 year, and the median time was 5.7 years (3.1-8.1 years). The incidence of ABMR and TCMR within the first year as well as (death-censored) graft survival is shown in Figure 3 . ABMR was significantly more frequent in the DSA group, while there were no differences among the three cPRA groups (p = 0.16). The incidence of TCMR was lower in the DSA group compared with the three cPRA groups, which we relate to the ATG induction in patients with pretransplantation DSA. However, we did again not observe a difference regarding the incidence of TCMR among the three cPRA groups (p = 0.75). Both deathcensored graft survival and graft survival did not differ among the cPRA groups (p = 0.28 and p = 0.92), while both were significantly lower in the DSA group (p = 0.0005 and p = 0.002, respectively). Among the 527 investigated transplantations, 90 were performed using FlowPRA SA analysis and 437 were performed using Luminex SA analysis. When only transplantations performed in the Luminex SA era were investigated, the results remained unchanged compared with the entire population ( Figure S1 ).
Detailed outcomes among the cPRA groups Next, we investigated the rejection episodes and outcomes in the three cPRA groups in detail (Table 2) . DGF occurred in around 20% of patients in all three groups (p = 0.99). The allograft biopsy frequency within the first year was similar among the three groups, and only 27 (6%) of 422 patients did not undergo a biopsy. The frequency of rejection episodes subdivided into clinical/subclinical ABMR/TCMR was not different among the three groups (p ≥ 0.31). The phenotypes of the first TCMR rejection episode were also similar among the cPRA groups (p = 0.62). In contrast, the phenotypes of the first ABMR rejection episode were slightly different, which was driven by a higher frequency of clinical mixed rejection episodes in the cPRA 51-100% group. Graft survival, death-censored graft survival, reason for graft failure, and reason for patient death were not different among the three cPRA groups. At last follow-up, median eGFR was 50-53 mL/min (p = 0.45), and median urine protein/creatinine ratios were 10-12 mg/mmol (p = 0.34).
In a further analysis, we correlated the cPRA values with the occurrence of rejection and allograft loss ( Figure 4 ). We did not observed significant differences in cPRA values between patients with versus those without (sub)-clinical ABMR, (sub)clinical TCMR, death-censored graft loss, and graft loss (all p ≥ 0.07).
Predictors of allograft rejection and loss
We used a Cox proportional hazard analysis to assess the predictive value of pretransplantation immunological variables (i.e. DSA status, peak cPRA, last cPRA, repeat transplantation status, history of pregnancies, HLA mismatches, and deceased donor status) on pertinent allograft outcomes ( Table 3 ). The presence of pretransplantation DSA was a strong and independent predictor for ABMR, death-censored graft loss, and graft loss. In contrast, peak and last cPRA values and repeat transplantation status were not predictive for any investigated outcome. HLA mismatches were predictive for TCMR and graft survival. The inverse cPRA, calculated population-reactive antibody; DSA, donor-specific HLA antibody; ADPKD, autosomal dominant polycystic kidney disease; PRA, panel-reactive antibody; MFI, mean fluorescence intensity; HD, hemodialysis; PD, peritoneal dialysis; Tac, tacrolimus; MPA, mycophenolic acid; P, prednisone; mTOR, mammalian target of rapamycin inhibitor (sirolimus or everolimus); IVIg, intravenous immunoglobulin; DD, deceased donor.
association of pretransplantation DSA with TCMR is likely related to ATG induction in this group (see earlier and Figure 3 ).
Pretransplantation DSA characteristics and risk of allograft rejection and loss Pretransplantation DSA characteristics were investigated regarding prediction of ABMR, any rejection, and deathcensored allograft loss ( Figure 5 ). The class and the number of DSA were not predictive for any outcome. In contrast, the strength of DSA defined by the highest individual MFI value or the cumulative MFI value of all DSA was associated with the occurrence of clinical ABMR, (sub)clinical ABMR, and any rejection. The AUC vaues were only moderate, ranging from 0.63 to 0.77; the calculated MFI cutoff varied between 988 and 5371 depending on the rejection phenotype(s) used as the outcome. We did not observe a correlation of pretransplantation DSA MFI and death-censored graft loss.
Impact of cPRA in the absence of pretransplantation DSA assignment Finally, we performed an analysis of the major outcomes, when transplantations with pretransplantation DSA were incorporated into the three cPRA groups and not treated as an independent group. This allowed exploring the impact of cPRA when pretransplantation DSA assignment is neglected. In contrast to the original analysis, we observed now significant differences in the incidence of ABMR and graft survival among the three cPRA groups (p < 0.0001 and p = 0.008, respectively) ( Figure S2 ).
Discussion
The key observation in this study is that cPRA per se do not imply an immunological risk when modern DSA assignment is used. This conclusion is supported by univariate and multivariate statistical analyses as well as the reconstitution of the cPRA effect when DSA assignment is neglected. Our results confirm the results of the study by Dunn et al and expand its applicability to patients without DSA, who are treated without T cell-depleting induction therapy (13) .
The most significant immunological pretransplantation risk factor in our study was the presence of DSA. In addition, the number of HLA mismatches was associated with a higher risk of TCMR and inferior allograft survival.
In contrast, other available pretransplantation immunological parameters such as repeat transplantation status and peak/last cPRAvalues were not predictive for the occurrence of ABMR, TCMR, or graft survival. This is consistent with a concept, which defines immunological risk primarily on the presence/absence of donor-specific memory and the load of foreign HLA antigens that can induce a de novo immune response (23, 24) .
What are the potential clinical implications of this study?
In an individual kidney transplant program, pretransplantation DSA and the number of HLA mismatches might be used to select the induction therapy and the maintenance immunosuppression regimen. For future clinical trials, assignment as "high-risk transplant" by the use of DSA rather than cPRA and/or repeat transplantation might be more accurate and allows for an enrichment of the target population. This would improve the capability to detect an effect of novel therapeutic interventions. Despite the wide adoption of cPRA determined by SAB as a measure of sensitization, there are very few publications investigating the association of cPRA with the occurrence of rejection and long-term allograft survival. To the best of our knowledge, only the study by Huber et al and our analysis are available so far (25) . Huber et al investigated 726
transplantations and found cPRA value to be a significant risk factor for lower death-censored allograft survival. This is contradictory to our results. However, in this study a clear separation and/or exclusion of patients with pretransplantation DSA was not mentioned, which might confound the results and conclusion. An interesting observation in our study was that the route of the sensitizing event correlates with the broadness of sensitization in the population. Prior transplantation was the most immunogenic event, followed by pregnancies and blood transfusions, which is consistent with a recent study investigating 553 patients (26) . Around 30% of patients without any known sensitizing events showed cPRA >0%; 5% of patients even had cPRA > 50%. HLA antibodies in patients without known sensitizing event might be related to false-positive SAB analyses (i.e. due to denatured antigens), unrecognized abortions in women, and heterologous immunity (27) (28) (29) .
In our cohort, the class and number of pretransplantation DSA were not predictive for the occurrence of rejection and death-censored graft loss. However, the strength of DSA had a moderate predictive value for the occurrence ABMR as well as any rejection, which is consistent with a recent publication (30) . Interestingly, the calculated optimal MFI cutoff was dependent on the definition of the investigated outcome. This suggests that increasing strength of DSA might have some predictive value, but there is no universally applicable cutoff that can be reliably used in clinics. Two very elegant studies demonstrated that the magnitude and the durability of the memory response in DSA patients are likely the key factors for the occurrence of ABMR and graft loss (31, 32) . Unfortunately, it seems that the strength of DSA at the time of transplantation is not very helpful to predict this memory response (31, 32) .
We used the last cPRA value in our study to assess the broadness of sensitization, because it is clearly defined and available for all patients. Peak cPRA value might be even more accurate, but its calculation is dependent on the availability of a serum obtained at the presumed "peak" antibody time point. Such sera are often not available, especially when the sensitizing events happened a long time ago. Interestingly, Huber et al found that cPRA and peak PRA values were equivalent to define highly sensitized patients and to predict long-term graft survival (25) . Further, we observed a rather small difference between peak cPRA and last cPRA values.
Our study had several advantages to investigate the impact of cPRA values on pertinent transplant outcomes. The study population had a reasonable size (i.e. n = 527), was well risk stratified according to the presence/ absence of pretransplantation DSA, had surveillance biopsies at 3 and 6 months posttransplantation, and had a median follow-up of 5.7 years. Further, cPRA calculation was exclusively based on SAB results, which make the cPRA values robust throughout the time frame of the study from 2005 to 2014.
The study also had some limitations. First, it is a singlecenter analysis in a Caucasian population. Therefore, the results still might need confirmation in other ethnicities from other transplant centers. Notably, the seminal study of Dunn et al, which is consistent with our results, was also performed in a predominantly Caucasian population (i.e. around 80%) (13) . Second, the group with cPRA 51-100% was rather small (i.e. n = 43) and thus might limit our ability to detect small differences, which might still be regarded as clinically relevant. Third, the cPRA calculation did not include HLA-C and -DP antibodies, because the majority of the 1584 persons used to calculate the cPRA values were not typed for HLA-C and -DP. Although the calculated cPRA in our study might therefore be underestimated, we do not assume that this would largely change the results. Fourth, our results were derived from a cohort in which an MFI > 500 cutoff was used for a positive SAB result as in the study by Dunn et al (13) . Thus, the conclusions might not be directly transferable to centers using a higher MFI cutoff. Indeed, a higher MFI cutoff (e.g. 2000) might lead to some misclassification of patients with weak DSA values, which will appear in the cPRA groups and eventually "convert" cPRA into a significant immunological risk factor.
In conclusion, cPRA values per se do not confer an immunological risk when modern DSA assignment is used. While DSA can be regarded as the most important immunological pretransplantation risk factor, the utility of cPRA is mainly to enhance access of sensitized patients to suitable organs in allocation systems (9, 33, 34) . 
